Investment Rating - The investment rating for the company is "Accumulate (Maintain)" with a current price of 23.65 yuan [1] Core Views - The company reported a significant increase in revenue and net profit for the year 2025, with revenue reaching 406 million yuan, a year-on-year growth of 19.62%, and net profit of 62.73 million yuan, up 46.39% year-on-year, indicating better-than-expected performance [4][7] - The company's three main business segments are driving revenue growth, with the vaccine culture medium business recovering post-pandemic, the food nutrition segment contributing stable growth, and the raw material drug business benefiting from inventory digestion in the distribution sector [7] - The report maintains an "Accumulate" rating, with adjusted profit forecasts for 2025-2027, expecting revenues of 405.49 million yuan, 480.26 million yuan, and 564.06 million yuan, respectively, and net profits of 62.73 million yuan, 69.42 million yuan, and 88.16 million yuan, respectively [7] Financial Performance Summary - For 2025, the company achieved total revenue of 406 million yuan, a 19.62% increase, and a net profit of 62.73 million yuan, reflecting a 46.39% increase year-on-year [4][7] - The company's basic earnings per share (EPS) for 2025 is projected at 0.81 yuan, a 47.27% increase compared to the previous year [7] - The total assets at the end of 2025 reached 890 million yuan, a 10.63% increase from the beginning of the year, while the net assets attributable to shareholders were 710 million yuan, with a net asset per share of 9.14 yuan, up 7.53% [7] Financial Forecasts - Revenue forecasts for 2023A, 2024A, 2025E, 2026E, and 2027E are 389.06 million yuan, 338.98 million yuan, 405.49 million yuan, 480.26 million yuan, and 564.06 million yuan, respectively [6] - Net profit forecasts for the same years are 53.41 million yuan, 42.85 million yuan, 62.73 million yuan, 69.42 million yuan, and 88.16 million yuan, respectively [6] - The projected P/E ratios for 2025-2027 are 29.29, 26.47, and 20.84 times, respectively [7]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company is expected to achieve a net profit attributable to shareholders of 63 million yuan in 2025, representing a year-on-year increase of 46%. The growth is supported by the expansion into overseas markets and new application fields [5][8] - The company's revenue for 2025 is projected to be 406 million yuan, reflecting a year-on-year growth of 19.62%. This growth is driven by the synergy of three major business segments: vaccine culture media, food nutrition products, and raw materials [8] - The company is actively establishing overseas subsidiaries to enhance market presence and streamline trade processes, which is expected to contribute to long-term growth [8] Financial Summary - Revenue Forecast: - 2023: 389 million yuan - 2024: 339 million yuan (decrease of 12.87%) - 2025E: 406 million yuan (increase of 19.62%) - 2026E: 482 million yuan (increase of 18.98%) - 2027E: 573 million yuan (increase of 18.73%) [7] - Net Profit Forecast: - 2023: 53 million yuan - 2024: 43 million yuan (decrease of 19.76%) - 2025E: 63 million yuan (increase of 46.38%) - 2026E: 79 million yuan (increase of 25.87%) - 2027E: 97 million yuan (increase of 23.12%) [7] - Earnings Per Share (EPS): - 2023: 0.69 yuan - 2024: 0.55 yuan - 2025E: 0.81 yuan - 2026E: 1.02 yuan - 2027E: 1.25 yuan [7] - Price-to-Earnings Ratio (P/E): - 2025E: 29.29 - 2026E: 23.27 - 2027E: 18.90 [7]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2] Core Insights - The company is expected to see a 46.39% year-on-year increase in net profit attributable to shareholders, with projected revenue of 406 million yuan for 2025 [4] - The core business segments are experiencing a recovery in demand, contributing to stable revenue and profit growth [4] - The company is actively expanding into new product categories and enhancing its overseas business presence [5] Financial Summary - Total revenue is projected to grow from 389 million yuan in 2023 to 662 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 23.7% [7] - Net profit attributable to shareholders is expected to increase from 53 million yuan in 2023 to 103 million yuan in 2027, with a significant growth rate of 18.4% in 2027 [7] - The company's gross margin is projected to stabilize around 30.6% from 2026 onwards [8] Business Development - The company has established a presence in overseas markets, with external sales accounting for approximately 56.88% of total revenue as of Q3 2025 [5] - New factories are in trial production, which will help address capacity constraints once regulatory approvals are obtained [5] - The company plans to diversify its product offerings beyond amino acids to include derivatives, functional peptides, and other innovative products [4]

Industry Overview - Peptides are bioactive fragments of proteins that can be rapidly absorbed and utilized by the human body, providing energy and nutrients to cells. Their potential has been further released since the Human Genome Project in the 1990s, leading to unprecedented prosperity in peptide research and applications, especially in the pharmaceutical field [1][13] - The Chinese peptide industry market size is projected to grow from 57.34 billion yuan in 2016 to 209.12 billion yuan in 2024, with a compound annual growth rate (CAGR) of 17.56%. By 2025, the market size is expected to reach approximately 247.6 billion yuan [1][13] Market Segmentation - The peptide industry value chain consists of upstream raw materials and equipment (amino acids, amino acid protectants, resin acids, synthesis instruments, packaging materials), midstream production and manufacturing, and downstream applications in food, pharmaceuticals, feed, health products, and cosmetics [9][11] - The global peptide drug market is expected to reach approximately 96 billion USD by 2025, driven by the increasing prevalence of chronic diseases and the unique advantages of peptide drugs in treatment [12][17] Key Companies - HanYue Pharmaceutical focuses on four main areas: peptide formulations, raw materials, small nucleic acids, and CRDMO services. The company has achieved significant revenue growth, with a reported 114.86% increase in pharmaceutical manufacturing revenue in the first half of 2025 [20][21] - ZhongPeptide Biochemical Co., Ltd. specializes in contract research, development, and production of peptides and small nucleic acids, providing comprehensive services from early discovery to commercial production [21] Development Trends - The Chinese peptide industry is transitioning from traditional chemical synthesis to a deep integration of biotechnology and synthetic biology, enhancing production efficiency and reducing costs [22][24] - The application of peptides is rapidly expanding beyond pharmaceuticals into health, beauty, and functional food markets, with increasing consumer demand for personalized health solutions [23][24] - The industry is also moving towards green manufacturing and sustainable development, focusing on reducing environmental footprints and enhancing social responsibility [24]

Financial Performance - The company achieved operating revenue of ¥405,501,949.74, an increase of 19.62% compared to the previous year[3] - The total profit reached ¥71,916,721.41, reflecting a growth of 41.53% year-on-year[3] - Net profit attributable to shareholders was ¥62,730,981.38, up 46.39% from the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥63,315,536.88, representing a 53.23% increase year-on-year[3] - Basic earnings per share rose to ¥0.81, a 47.27% increase compared to the previous year[3] Assets and Equity - Total assets at the end of the reporting period were ¥889,388,272.66, a growth of 10.63% from the beginning of the period[4] - Shareholders' equity attributable to the company increased to ¥710,073,877.18, up 7.51% from the beginning of the period[4] Revenue Drivers - The company's three main business segments contributed to revenue growth: vaccine culture media, food nutrition products, and raw materials[6] - Profit growth was driven by steady revenue increase, cost structure optimization, and improved operational efficiency[7] Financial Data Disclaimer - The company warns that the financial data presented is preliminary and subject to change upon final audit[8]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the coming months [5]. Core Insights - The company is expected to achieve a net profit of 60-66 million yuan in 2025, representing a year-on-year growth of 40.0-54.0%. The fourth quarter alone is projected to see a net profit of 11.94-17.94 million yuan, with a significant year-on-year increase of 154.7-282.7% [5]. - Demand recovery across various application fields is driving simultaneous growth in revenue and profit. The market demand is returning to normal levels, particularly in the cultivation substrate sector, while the nutritional food sector benefits from ongoing market recovery [5]. - Cost structure optimization is contributing positively to profit margins, with a reduction in certain expenses, including employee stock incentive costs and impairment provisions, easing cost pressures [5]. - The company is expanding its overseas presence by establishing subsidiaries in the Netherlands and the United States, aiming to tap into the overseas raw material market and address capacity shortages in other sectors [5]. Financial Data and Profit Forecast - Total revenue is projected to grow from 404 million yuan in 2025 to 622 million yuan in 2027, with year-on-year growth rates of 19.2%, 25.3%, and 22.9% respectively [4]. - The net profit forecast for 2025 is 63 million yuan, increasing to 108 million yuan by 2027, with corresponding growth rates of 47.3%, 32.2%, and 29.6% [4]. - Earnings per share are expected to rise from 0.81 yuan in 2025 to 1.39 yuan in 2027, reflecting the company's improving profitability [4].

Investment Rating - The report maintains a rating of "Outperform" for the company, indicating a positive outlook compared to the market [6]. Core Insights - The company's performance in 2025 is expected to meet forecasts, with a projected net profit of 60-66 million yuan, representing a year-on-year growth of 40.0-54.0% [6]. - Demand recovery is driving simultaneous growth in revenue and profit, particularly in various application fields such as culture media and nutritional products [6]. - Cost structure optimization is contributing positively to profit margins, with a reduction in certain expenses alleviating cost pressures [6]. - The company is set to release new production capacity and establish overseas subsidiaries to support market expansion [6]. - Long-term performance is expected to remain stable, with revenue forecasts for 2025-2027 at 404 million, 506 million, and 622 million yuan respectively, and corresponding net profits of 63 million, 83 million, and 108 million yuan [6]. Financial Data and Profit Forecast - Total revenue is projected to grow from 404 million yuan in 2025 to 622 million yuan in 2027, with a compound annual growth rate of approximately 22.9% [5]. - The net profit is expected to increase from 63 million yuan in 2025 to 108 million yuan in 2027, reflecting a strong growth trajectory [5]. - The company's gross margin is forecasted to remain stable around 31% to 32% over the next few years [5].

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Financial Forecast - The company forecasts a net profit of between 6,000.00 and 6,600.00 million CNY for 2025, representing an increase of 40.02% to 54.02% compared to the previous year's profit of 4,285.10 million CNY[4] - The performance forecast is preliminary and has not yet been audited by an accounting firm, urging investors to be aware of investment risks[6] Performance Drivers - The growth in performance is attributed to a recovery in core business demand, particularly in vaccine culture media, food nutrition products, and raw materials, which collectively drove significant revenue and profit increases[5] - Cost structure optimization contributed positively to profit, with a reduction in related expenses by approximately 2.5 million CNY due to the completion of employee stock incentive amortization[5]

东方证券股份有限公司 关于无锡晶海氨基酸股份有限公司 使用闲置募集资金进行现金管理的核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为无锡晶海 氨基酸股份有限公司（以下简称"无锡晶海"或"公司"）本次向不特定合格投资者 公开发行股票并在北京证券交易所上市的保荐机构，根据《北京证券交易所上市公 司持续监管办法（试行）》《北京证券交易所证券发行上市保荐业务管理细则》《北京 证券交易所股票上市规则》等有关规定，对无锡晶海使用闲置募集资金进行现金管 理事项进行了核查，具体情况如下： 一、募集资金基本情况 无锡晶海于 2023 年 9 月 28 日收到中国证券监督管理委员会下发的《关于同意无 锡晶海氨基酸股份有限公司向不特定合格投资者公开发行股票注册的批复》（证监许 可〔2023〕2262 号），同意公司向不特定合格投资者公开发行股票的注册申请。公司 本次发行的发行价格为 16.53 元/股，募集资金总额人民币 25,786.80 万元，减除发行 费用人民币 2,704.00 万元（不含税）后，募集资金净额为人民币 23,082.80 万元。截 至 2023 年 12 月 4 日，上述募集资金已到 ...